BACKGROUND: Recurrent stroke rates after intracerebral hemorrhage (ICH) vary widely between observational studies due to differences in ICH etiology and risk for thromboembolic events. We therefore aimed to assess the patient characteristics and prognosis after deep and lobar ICH in a well-characterized, multicenter, hospital-based cohort. METHODS: Patients were prospectively documented in 13 German neurological stroke centers. Of 744 patients with spontaneous ICH discharged alive, 516 (69.4%) gave informed consent and 496 (66.7%) could be followed up by central telephone interview over a mean duration of 2 years. RESULTS: In patients with deep ICH, the Kaplan-Meier estimate for stroke during the first year was 5.8% (95% CI 2.9-8.7) and the overall annual rate (calculated over a 3-year period) was 2.9% (95% CI 1.6-4.1). In patients with lobar ICH, the Kaplan-Meier estimate for stroke during the first year was 7.8% (95% CI 3.1-12.5) and the overall annual rate was 7.2% (95% CI 3.8-10.6). At the last follow-up before recurrent stroke or end of study, 141 patients (28.4%) overall received antiplatelet agents, and 12 (2.4%) received oral anticoagulation. No difference could be found for recurrent ICH under antiplatelet agents versus no antithrombotic medication. CONCLUSION: The risk of recurrent stroke after lobar ICH remains high beyond the first year, whereas it decreases after 1 year in patients with deep ICH. Antiplatelets are prescribed in a considerable number of patients even though the risk-benefit ratio after ICH remains unknown.
BACKGROUND: Recurrent stroke rates after intracerebral hemorrhage (ICH) vary widely between observational studies due to differences in ICH etiology and risk for thromboembolic events. We therefore aimed to assess the patient characteristics and prognosis after deep and lobar ICH in a well-characterized, multicenter, hospital-based cohort. METHODS:Patients were prospectively documented in 13 German neurological stroke centers. Of 744 patients with spontaneous ICH discharged alive, 516 (69.4%) gave informed consent and 496 (66.7%) could be followed up by central telephone interview over a mean duration of 2 years. RESULTS: In patients with deep ICH, the Kaplan-Meier estimate for stroke during the first year was 5.8% (95% CI 2.9-8.7) and the overall annual rate (calculated over a 3-year period) was 2.9% (95% CI 1.6-4.1). In patients with lobar ICH, the Kaplan-Meier estimate for stroke during the first year was 7.8% (95% CI 3.1-12.5) and the overall annual rate was 7.2% (95% CI 3.8-10.6). At the last follow-up before recurrent stroke or end of study, 141 patients (28.4%) overall received antiplatelet agents, and 12 (2.4%) received oral anticoagulation. No difference could be found for recurrent ICH under antiplatelet agents versus no antithrombotic medication. CONCLUSION: The risk of recurrent stroke after lobar ICH remains high beyond the first year, whereas it decreases after 1 year in patients with deep ICH. Antiplatelets are prescribed in a considerable number of patients even though the risk-benefit ratio after ICH remains unknown.
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Miriam R Raffeld; Alessandro Biffi; Thomas W K Battey; Alison M Ayres; Anand Viswanathan; Steven M Greenberg; Jonathan Rosand; Christopher D Anderson Journal: Neurology Date: 2015-06-26 Impact factor: 9.910
Authors: Eric M Liotta; Mandeep Singh; Adam R Kosteva; Jennifer L Beaumont; James C Guth; Rebecca M Bauer; Shyam Prabhakaran; Neil F Rosenberg; Matthew B Maas; Andrew M Naidech Journal: Crit Care Med Date: 2013-12 Impact factor: 7.598
Authors: Santosh B Murthy; Xian Wu; Ivan Diaz; Melvin Parasram; Neal S Parikh; Costantino Iadecola; Alexander E Merkler; Guido J Falcone; Stacy Brown; Alessandro Biffi; Judy Ch'ang; Jared Knopman; Philip E Stieg; Babak B Navi; Kevin N Sheth; Hooman Kamel Journal: Stroke Date: 2020-03-17 Impact factor: 7.914
Authors: Ching-Jen Chen; Dale Ding; Thomas J Buell; Fernando D Testai; Sebastian Koch; Daniel Woo; Bradford B Worrall Journal: Neurology Date: 2018-05-30 Impact factor: 9.910
Authors: Linxin Li; Michael T C Poon; Neshika E Samarasekera; Luke A Perry; Tom J Moullaali; Mark A Rodrigues; James J M Loan; Jacqueline Stephen; Christine Lerpiniere; Maria A Tuna; Sergei A Gutnikov; Wilhelm Kuker; Louise E Silver; Rustam Al-Shahi Salman; Peter M Rothwell Journal: Lancet Neurol Date: 2021-06 Impact factor: 59.935